INSIGHT 2 Primary Analysis
Phase II INSIGHT 2: Primary Analysis of Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib

Released: September 20, 2023

Activity

Progress
1
Course Completed